A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Recruiting now · Phase 1
Conditions studied: Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
In brief
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \[CAR\] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.
Key facts
- Study ID
- NCT07544589
- Run by
- Dispatch Biotherapeutics
- People needed
- 66
- Starts
- 2026-04-01
- Expected to finish
- 2046-04-01
- Last updated by the study team
- 2026-05-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States (enrolling)
- University of Cincinnati Cancer Center — Cincinnati, Ohio, United States (enrolling)
- Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.